Pharma’s post-pandemic launch performance problem: what’s the prognosis?
pharmaphorum
JUNE 29, 2022
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face.
59 
Let's personalize your content